Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large
Bioethics · 2026-06 · 40 (5) · 505-518
DOI: 10.1111/bioe.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioethics, online erschienen am 07.12.2025. Verfasst von Francesca Minerva. Beteiligte Einrichtung: University of Milan-Department of Philosophy, Milan, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: University of Milan, Grant/Award Number: P20225A73K_003; Ministry of University and Research..
Abstract (Originalsprache)
This paper explores the ethical implications of emerging weight‐loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long‐term side effects, the exacerbation of weight‐based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Milan-Department of Philosophy, Milan, Italy.
ORCID-Profile: Francesca Minerva
Förderung
- University of Milan, Grant/Award Number: P20225A73K_003; Ministry of University and Research.
Zitieren
APA
Minerva, F. (2026). Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large. Bioethics, 40(5), 505-518. https://doi.org/10.1111/bioe.70068
Vancouver
Minerva F. Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large. Bioethics. 2026;40(5):505-518. doi:10.1111/bioe.70068
BibTeX
@article{Minerva2026,
author = {Minerva, Francesca},
title = {Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large},
journal = {Bioethics},
year = {2026},
volume = {40},
number = {5},
pages = {505--518},
doi = {10.1111/bioe.70068}
}
EUVIMED